AbbVie Inc (ABBV)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

1 NORTH WAUKEGAN ROAD NORTH CHICAGO, IL 60064

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. AbbVie is a wholly owned subsidiary of Abbott Laboratories (Abbott). AbbVie's portfolio of products includes a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

Data based on most recent fiscal year report
Market Cap144.621 Billion Shares Outstanding1.596 Billion Avg Volume9.865 Million
1-Yr BETA vs S&P TR Current Ratio1.28 Quick Ratio1.18
View SEC Filings from ABBV instead.
Q1 2019 All Institutions Hedge Funds 1
To trade ABBV now:
Filers who had this stock in their top 10: 59 8 (0.82%)
13F Filers holding this stock: 1950 137 (13.97%)
Aggregate 13F shares on 03/31/2019: 1.008 Billion 40.135 Million
Aggregate 13F shares on 12/31/2018: 1.043 Billion 24.728 Million
Percent change: -3.43% 62.31%
Funds creating new positions: 120 27
Funds Adding to an existing position: 753 40
Funds closing out their position: 128 12
Funds reducing their position: 865 53
Heat Map Ranking for 03/31/2019 18
Heat Map Ranking for 12/31/2018 63
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

 

AbbVie Inc Chart by YCharts

Yahoo! Finance

finviz

Check out our reporting and analysis

Funds Holding ABBV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SCHUMACHER LAURA J

  • Director
 5,073 2019-06-18 8

AUSTIN ROXANNE S

  • Director
 42,532 2019-06-13 1

ALPERN ROBERT J

  • Director
 167,390 2019-05-31 5

ROBERTS REBECCA B

4,670 2019-05-31 1

MEYER MELODY B

  • Director
 12,648 2019-05-28 1

FREYMAN THOMAS C

  • Director
 19,988 2019-05-23 0

LEONARD JOHN M.

  • Director
 8,252 2019-05-16 0

GOSEBRUCH HENRY O

  • Director
 0 2019-05-15 4

LIDDY EDWARD M

  • Director
 56,924 2019-05-14 5

WADDELL FREDERICK H

  • Director
 19,548 2019-05-03 1

TILTON GLENN F

  • Director
 42,504 2019-05-03 2

RAPP EDWARD J

  • Director
 23,162 2019-05-03 5

BURNSIDE WILLIAM H.L.

  • Director
 17,548 2019-05-03 1

HART BRETT J

  • Director
 10,062 2019-05-03 1

SALEKI-GERHARDT AZITA

  • Director
 11,556 2019-05-01 3

DURKIN BRIAN L VP, CONTROLLER

  • Officer
 9,374 2019-03-25 4

CHASE WILLIAM J EVP, FINANCE & ADMINISTRATION

  • Officer
 139,653 2019-02-28 3

ALBAN CARLOS VICE CHAIRMAN

  • Officer
 168,319 2019-02-28 2

RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER

  • Officer
 15,515 2019-02-28 2

GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO

  • Officer
  • Director
 382,538 2019-02-28 4

SEVERINO MICHAEL VICE CHAIRMAN

  • Officer
 115,857 2019-02-28 3

MICHAEL ROBERT A. SVP, CHIEF FINANCIAL OFFICER

  • Officer
 10,913 2019-02-28 2

STEWART JEFFREY RYAN SVP, US COMMERCIAL OPERATIONS

  • Officer
 49,752 2019-02-28 5

DONOGHOE NICHOLAS SVP, ENTERPRISE INNOVATION

  • Officer
 0 2019-02-21 3

HURWICH THOMAS A. VP, CONTROLLER

  • Officer
 No longer subject to file 2017-02-28 0

ROBERTS ROY S

  • Director
 27,486 2015-05-08 0

LINDER GREG W VICE PRESIDENT

  • Officer
 No longer subject to file 2013-02-28 0

ABBOTT LABORATORIES

  • 10% Owner
 0 2012-12-12 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BURNSIDE WILLIAM H.L. - Director

2019-05-03 A 2,419 a 17,548 17,548.00 direct

AUSTIN ROXANNE S - Director

2019-05-03 A 2,419 a 40,614 40,614.00 direct

MEYER MELODY B - Director

2019-05-03 A 2,419 a 7,088 7,088.00 direct

TILTON GLENN F - Director

2019-05-03 A 2,419 a 42,154 42,504.00 direct

HART BRETT J - Director

2019-05-03 A 2,419 a 10,062 10,062.00 direct

RAPP EDWARD J - Director

2019-05-03 A 2,419 a 23,162 23,162.00 direct

WADDELL FREDERICK H - Director

2019-05-03 A 2,419 a 19,548 19,548.00 direct

ALPERN ROBERT J - Director

2019-05-03 A 2,419 a 26,107 26,107.00 direct

LIDDY EDWARD M - Director

2019-05-03 A 2,419 a 22,669 22,669.00 direct

ROBERTS REBECCA B - Director

2019-05-03 A 2,419 a 4,318 4,318.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments